Digital Health: Diabetes Apps and Virtual Coaching
Digital Health: Diabetes Apps and Virtual Coaching
$2,250.00
Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Highlights
- This technology-based report provides an overview of diabetes, wearable glucose monitoring devices, and smartphone-based digital health technologies
- Digital health is expected to transform the diabetes management market over the next decade substantially improving outcomes and reducing healthcare costs
- This report therefore attempts to answer the question: can digital health help improve diabetes?
- Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices, including new continuous glucose monitoring systems/CGMs, and personalized “virtual diabetes coaching”
- The adoption of digital health technologies for diabetes management is being driven by:
- the large and growing prevalence of diabetes
- heavy patient burden and treatment complexity
- poorly controlled diabetes
- spiraling diabetes-related healthcare costs
- the rise in global smartphone usage and increased accessibility to smartphone-based “telehealth”
- positive clinical data showing reduced complications and healthcare costs.
Key topics covered
- An overview of diabetes and prevalence
- Diabetes smartphone apps
- Digital therapeutics/diabetes coaching platforms
- Blood glucose monitoring technologies
- Clinical data
- Limitations
- Companies discussed in this report: Abbott, Ascensia Diabetes Care, Dario Health, Dexcom, Glooko, IBM Watson Health, Insulet Corporation, Lark Technologies, LifeScan, Livongo Health, Medtronic, mySugr, Nemaura Medical, Omada Health, Onduo, One Drop, Roche, Sanofi, Senseonics, Tandem Diabetes Care, Virta Health, and Welldoc.
Overview
This special technology-based report provides an overview of diabetes, wearable glucose monitoring devices, smartphone-based digital health technologies, and attempts to answer the question: can digital health help improve diabetes?
Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.
The adoption of smartphone-based digital health technologies for diabetes management is being driven by:
- the large and growing prevalence of diabetes
- heavy patient burden and treatment complexity
- poorly controlled diabetes
- spiraling diabetes-related healthcare costs
- the rise in global smartphone usage and increased accessibility to smartphone-based “telehealth”
- positive clinical data supporting reduced complications and healthcare costs.
Companies discussed in this report: Abbott, Ascensia Diabetes Care, Dario Health, Dexcom, Glooko, IBM Watson Health, Insulet Corporation, Lark Technologies, LifeScan, Livongo Health, Medtronic, mySugr, Nemaura Medical, Omada Health, Onduo, One Drop, Roche, Sanofi, Senseonics, Tandem Diabetes Care, Virta Health, and Welldoc.
Executive Summary……………………………………………………………………. ES-1
i. Digital health is transforming diabetes management ……………………………………………….ES-1
ii. Benefits ……………………………………………………………………………………………………………..ES-1
iii. Clinical data ……………………………………………………………………………………………………….ES-2
iv. Limitations…………………………………………………………………………………………………………ES-2
v. Security concerns………………………………………………………………………………………………..ES-2
vi. Conclusion …………………………………………………………………………………………………………ES-2
vii. Bibliography………………………………………………………………………………………………………ES-4
1. Diabetes Overview ……………………………………………………………………1-1
1.1 Type 1 diabetes: 5% of the diabetes population are insulin dependent……………………. 1-1
1.2 Type 2 diabetes: 95% of the diabetes population ………………………………………………….. 1-1
1.3 Diabetes prevalence: rising by 50% over next 25 years ………………………………………….. 1-1
1.4 Complications: tight glycemic control can prevent complications……………………………. 1-2
1.5 Prevention………………………………………………………………………………………………………… 1-2
1.6 Bibliography ……………………………………………………………………………………………………… 1-3
2. New Guidelines for Achieving Glycemic Control …………………………….2-1
2.1 ADA’s target A1c: 2019 Standards of Medical Care in Diabetes……………………………….. 2-1
2.2 The importance of self-monitoring of blood glucose ……………………………………………… 2-1
2.3 The DCCT study …………………………………………………………………………………………………. 2-2
2.4 New 2019 ADA guidelines for glycemic targets: time-in-range……………………………….. 2-2
2.5 Medtronic’s TIR goals…………………………………………………………………………………………. 2-4
2.6 Bibliography ……………………………………………………………………………………………………… 2-5
3. Blood Glucose Monitoring and the Rise of Smartphone-Driven Diabetes Apps…………………………………………………………………..3-1
3.1 Ascensia …………………………………………………………………………………………………………… 3-3
3.2 DarioHealth………………………………………………………………………………………………………. 3-3
3.3 LifeScan……………………………………………………………………………………………………………. 3-4
3.4 Welldoc’s BlueStar for diabetes………………………………………………………………………….. 3-6
3.5 Glooko……………………………………………………………………………………………………………… 3-8
3.6 mySugr …………………………………………………………………………………………………………….. 3-9
3.7 Bibliography ……………………………………………………………………………………………………. 3-11
Exhibit 3-1: Selected standard blood glucose meters and diabetes apps ………………………………. 3-2
Exhibit 3-2: OneTouch Verio Flex and OneTouch Reveal app……………………………………………….. 3-4
Exhibit 3-3: OneTouch Reveal Plus powered by Welldoc’s BlueStar technology …………………….. 3-5
Exhibit 3-4: Welldoc’s BlueStar AI-driven smart diabetes app ……………………………………………… 3-7
Exhibit 3-5: Glooko Mobile app………………………………………………………………………………………… 3-8
Exhibit 3-6: mySugr app ………………………………………………………………………………………………….. 3-9
4. Virtual Diabetes Coaching…………………………………………………………..4-1
4.1 Lark Technologies ……………………………………………………………………………………………… 4-1
4.2 Livongo…………………………………………………………………………………………………………….. 4-1
4.3 Onduo ……………………………………………………………………………………………………………… 4-2
4.4 One Drop………………………………………………………………………………………………………….. 4-4
4.5 Virta Health………………………………………………………………………………………………………. 4-5
4.6 Bibliography ……………………………………………………………………………………………………… 4-8
Exhibit 4-1: Onduo for diabetes……………………………………………………………………………………….. 4-3
Exhibit 4-2: The One Drop digital diabetes management portfolio……………………………………….. 4-5
Exhibit 4-3: Virta app………………………………………………………………………………………………………. 4-6
5. Revolutionary Continuous Glucose Monitoring Systems………………….5-1
5.1 Abbott ……………………………………………………………………………………………………………… 5-3
5.2 Dexcom ……………………………………………………………………………………………………………. 5-7
5.3 Medtronic ………………………………………………………………………………………………………. 5-11
5.4 Nemaura Medical…………………………………………………………………………………………….. 5-13
5.5 Senseonics………………………………………………………………………………………………………. 5-14
5.6 Bibliography ……………………………………………………………………………………………………. 5-16
Exhibit 5-1: Selected continuous glucose monitoring systems with diabetes apps …………………. 5-2
Exhibit 5-2: The FreeStyle Libre CGM 14-day sensor and LibreLink app…………………………………. 5-4
Exhibit 5-3: The Dexcom G6 CGM System with extended 10-day sensor……………………………….. 5-9
Exhibit 5-4: Dexcom CLARITY diabetes management software…………………………………………… 5-10
Exhibit 5-5: The Guardian Connect CGM System with Sugar.IQ app……………………………………. 5-12
Exhibit 5-6: The SugarBEAT system…………………………………………………………………………………. 5-14
Exhibit 5-7: The Eversense CGM and mobile app ……………………………………………………………… 5-15
6. Clinical data – Can Digital Health Help Improve Diabetes?……………….6-1
6.1 Meaningful Reduction in HbA1c………………………………………………………………………….. 6-1
6.2 Clinical review of diabetes apps/digital health technologies …………………………………… 6-2
6.3 Emerging full-service virtual diabetes clinics…………………………………………………………. 6-6
6.4 Bibliography ……………………………………………………………………………………………………… 6-8
Exhibit 6-1: Selected studies, average reduction in HbA1c with use of diabetes apps and/ or digital app-based coaching programs …………………………………………………………….. 6-1
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Hemophilia KOL Interview – US, Southeast 
Sign up to the